



NDA 209510/S-004

SUPPLEMENT APPROVAL

Acacia Pharma Ltd
c/o Acacia Pharma Inc
Attention: Paul Orth
8440 Allison Pointe Blvd., Suite 100
Indianapolis, IN 46250

Dear Paul Orth:

Please refer to your Supplemental New Drug Application (sNDA) dated and received July 9, 2021, and your amendment, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Barhemsys (amisulpride) injection.

This Prior Approval supplemental new drug application provides for modifications to the full prescribing information in the US Package Insert (USPI) for the drug product as follows: modifications to section 2.2 to add new information regarding compatibility of the Barhemsys (amisulpride) injection product with Lactated Ringer's Solution.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the prescribing information) with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled *SPL Standard for Content of Labeling Technical Qs and As* at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled *SPL Standard for Content of Labeling Technical Qs and As* at

<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes, and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Grecia C. Edwards, Regulatory Business Process Manager, at (240) 402 - 1773.

Sincerely,

{See appended electronic signature page}

David Lewis, PhD.
Branch Chief, B2
Division of Post-Marketing Activities I
Office of Lifecycle Drug Products
Office of Pharmaceutical Quality
Center for Drug Evaluation and Research

Enclosure:
Content of Labeling



David
Lewis

Digitally signed by David Lewis

Date: 1/05/2022 06:21:08PM

GUID: 508da72000029f287fa31e664741b577